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Human immunodeficiency virus type 1 (HIV-1) Tat-mediated trans-activation requires the structural integrity of TAR RNA
and the cooperative interaction of human host cell proteins. The TAR domain, minimally required for tat response, includes
the Tat binding pyrimidine bulge, the TAR RNA upper stem, and the loop sequences. However, little is known about the
significance of the 5*-stem structure of TAR in the regulation of viral growth. We designed viral mutations, specifically in
the TAR RNA lower stem structure, and studied their effects on the kinetics of viral growth in T-lymphocyte cell lines and
in activated human peripheral blood mononuclear cells. Mutations that destabilized the lower TAR stem structure inhibited
viral growth to various degrees in different CD/4 T-cells. These results suggest that the structural integrity of the lower stem
structure of TAR plays an important role in viral growth, presumably by binding to specific host cell proteins that stabilize
Tat–TAR interactions. q 1996 Academic Press, Inc.
The Human Immunodeficiency virus type 1 (HIV-1) TAR may be quite different than viral constructs introduced
into cells by transient transfection. We suggest that spe-element is essential for Tat-mediated trans-activation of
viral genes, a step that is critical for productive viral cific host cell proteins that recognize the stem structure
of TAR RNA are significant in regulating viral growth.replication (1, 2). Tat-mediated trans-activation has been
proposed to play an essential role in increased viral repli- Earlier we reported the identification of a TAR RNA
stem binding protein, p140, from HeLa cell nuclear ex-cation associated with disease progression (3). A num-
ber of studies have suggested that host cell factors are tracts (14). Since the TAR RNA binding domain of p140
is distinct from the Tat binding site, as well as the hostnecessary for Tat function (4–9), and proteins that bind
specifically to TAR RNA domains have been identified protein binding six nucleotide loop sequences, and since
the TAR RNA p140 complex migrates slower in the pres-(10, 11–14); yet relatively little is known about the effects
of host factors and TAR RNA interactions on viral growth. ence of added Tat protein (17), we suggest that p140-
TAR RNA stem interaction acts to stabilize Tat–TAR inter-In a recent report Harrich et al. (15) analyzed the
changes in growth kinetics of viral mutants with alter- actions in vivo. To address the issue whether the integrity
of the TAR stem regulates viral growth, we constructedations in the TAR stem, the pyrimidine bulge, or the loop
sequences. Although these changes in TAR structure mutations in HIV-1 proviral DNA which destabilize p140
binding in in vitro gel shift assays, but do not disrupt Tatwere generally deleterious for viral gene expression and
replication, the perturbation of the upper portion of TAR binding. Growth kinetics of the viral mutants showed a
strict requirement for the base-paired lower TAR stemRNA stem structure was particularly severe for viral
growth. Notably, the effect of TAR mutations on viral structure in some T-cell types but not in others. A comple-
mentary mutation that restored the wild-type TAR struc-growth showed cell type differences, thus pointing to a
critical role of TAR binding cellular factors in the regula- ture, showed viral growth comparable to wild type in
three types of infected T-lymphocyte cell lines and intion of viral growth (15).
The TAR domain normally considered essential for tat PHA-stimulated human peripheral blood mononuclear
cells (PBMC).response consists of the upper TAR (/19 to /48) region,
which includes the Tat-binding pyrimidine bulge and the The parental HIV genomic construct, pILIC carrying
HIV genome with a single LTR (derived from pNL4-3; 18),loop sequence. Klaver and Berkhout have pointed out
(16) that the integrity of the base-paired lower stem re- was cloned into pUC8 vector (19). A BamHI/SphI frag-
ment containing the LTR was subcloned into the pSelectgion of TAR is essential for viral growth, suggesting that
the transcriptional requirements of an integrated provirus Vector (Promega, Madison, WI) in order to introduce the
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TABLE 1 stem III structure (14). The structural changes introduced
by VM37 mutation, however, do not compromise the TatRelative RT Activity (with Respect to Wild Type)
binding pyrimidine bulge or the stem IV and the loopof HIV-1 TAR Mutants
structure of TAR (Fig. 1). As shown in Fig. 2A, the VM37
Cell type mutation has little influence on the viral growth rate in
A3.01 MT4 cells or in PBMCs. Deletion of the non base-
Mutant MT4 A3.01 JE6.1 PBMS
paired A16 nucleotide in mutant VM39, which creates a
further stabilized TAR RNA stem structure, (DG-25 kCalWT-ILIC 1.0 (d4) 1.0 (d9) 1.0 (d9) 1.0 (d6)
VM39 1.0 (d4) 1.2 (d9) 0.8 (d9) 1.0 (d6) for wt TAR RNA to DG-28.3 kCal for TM39; 14), again
VMC4 1.0 (d4) 1.5 (d9) 0.5 (d9) 0.9 (d6) has little effect on viral growth kinetics in the T-cell lines
VM37 0.7 (d4) 1.0 (d9) 0.2 (d17) 0.9 (d6) or in PBMCs (Fig. 2A). The growth kinetics of these viral
VM3*23 0.8 (d6) 1.2 (d17) 0.1 (d24) 0.3 (d6)
mutants show that changes in TAR RNA structure thatVM5*23 0.6 (d6) 1.0 (d14) 0.02 (d28) 0.6 (d6)
lead to an altered TAR stem III domain or deletion of the
Note. The numbers in parenthesis represent the day of peak RT unpaired C4 or A16 nucleotides induce little change in
activity. viral growth rate.
Proviral mutations were also designed to evaluate the
effect of changes in the lower TAR stem structures (thedesired TAR mutations by using the ‘‘Altered Sites in vitro
p140 binding region) on viral growth (Fig. 2B). TheseMutagenesis System’’ (Promega, Madison, WI). The TAR
mutations were designed such that the mutant TAR RNAregion mutations were confirmed by DNA sequencing.
transcripts would have disrupted TAR RNA stem II andThe secondary structure of the TAR mutants was deter-
stem III regions due to nucleotide replacement at the 5*mined according to Steiger et al. (1981) (20), using
end (VM5*23) or the 3* end of the stem structureMCDNASIS Pro Software from Hitachi Software Engi-
(VM3*23). A complementary mutation (VM23) which usedneering Co., Ltd. (CA) (Fig. 1). The mutants were mobi-
both the 5*-23 and the 3*-23 oligonucleotides and re-lized into the single LTR HIV genomic vector, pILIC. To
stored the normal secondary structure of the stem re-generate dual LTR HIV genomes containing the intro-
gions II and III RNA (Fig. 1; the designation of the stem’sduced TAR region mutations, the mutant pILIC DNAs
domain is as described in Fig. 1 of the ref. 14).were linearized with BamHI and then concatemerized
The growth kinetics of the lower TAR stem mutatedwith T4 DNA ligase. The concatemerized HIV genomic
virions, as measured by RT activity, varied dependingDNA constructs were transfected into A3.01 cells (a
upon the host cell type. For instance, in A3.01 cells, theCEM-derived CD4 T cell line), which were then coculti-
peak of RT activity for the mutants VM5*23 and VM3*23vated with MT4 cells (another CD4 T-cell line which is
was delayed from 7 to 17 days. In JE6.1 cells, however,highly susceptible to HIV infection). The culture media
the RT activity in the VM5*23- and VM3*23-infected cellswas harvested and assayed for reverse transcriptase
was negligible even after 28 days postinfection (Fig. 2B).(RT) activity. The presence of the introduced mutations
The delay in the peak of RT activity in MT4 cells wasin MT4 cells infected with the viral stocks was confirmed
modest for each of the lower stem mutations. In PBMCs,by direct DNA sequencing of the PCR-amplified LTR
disruption of the lower TAR stem was accompanied byDNA. The culture medium with the viral stock was nor-
reduced virus production, which was restored to wild-malized for RT activity and used to infect A3.01, MT4,
type levels by the VM23 complementary mutation. Suchand JE6.1 (a Jurkat CD4/) cell lines and PHA-stimulated
cell type differences in viral growth rate could result fromPBMCs. All the infections were carried out in duplicate.
variation in the level of functional activation of the hostRepresentative data is presented here. Table 1 summa-
cell factors that specifically recognize the lower TARrizes the RT activities of HIV-1 mutants on the day of
stem domains and perhaps modulate the transcriptionaltheir peak activity, normalized to wild type virus. The
processes. Alternatively, upstream transcription factorsmedia from these infections were assayed for RT activity
could also influence mutant LTR function. It has beenfor up to 28 days postinfection.
previously shown (19), that high level of NFkB present inThe TAR mutant provirus VMC4 , with deletion of the
MT4 cells can obviate the requirement for Sp1 in infec-unpaired nucleotide C4 , showed little change in viral
tious viral clones lacking NFkB sites, whereas in A3.01growth kinetics in any of the three T-cell lines or in
cells with low levels of NFkB, the dependence on otherPBMCs (Fig. 2A). Mutant VM37 containing a C18 r A18
base substitution disrupts the short base paired TAR transcription factors, such as Sp1 or NFAT1 becomes
FIG. 1. RNA folding pattern of the wild-type TAR and the TAR mutant sequences constructed into the proviral DNA, pILIC. The following synthetic
oligodeoxynucleotides were used to generate the proviral DNA TAR region mutants: 5*23, GTACTGGGTCTCTCTTCAATCACCAGATCTGACCCT;
3*23, GGGAGCTCTCTGGGATTGGAGGGAACCCAGTGC. The mutant VMC4 has the unpaired nucleotides C4 deleted, VM37 contains C18 r A18
substitution, and VM39 contains deletion of unpaired A16 nucleotide. The mutant VM 5*23 contains substitution of nucleotides 10–15, while VM3*23
contains substitution of nucleotides 44–49. The mutant VM23 contains substitution at 10–15 and 44–49 nucleotides.
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FIG. 2. Kinetics of viral growth in three different T-cell lines, A3.01, MT4, and JE6.1- and PHA-stimulated human PBMCs. Wild-type and mutant
HIV genomic constructs were transfected in A3.01 cells followed by their cocultivation with MT4 cells. The resultant viral stock was then used to
infect various cell lines and PBMCs. Panels 2A shows the RT levels in cells infected with wild-type pILIC and a group of viral mutants, VMC4,
VM37, and VM39 that show little change in growth properties compared to the wild type. Panel 2B compares the growth kinetics of viral mutants,
VM5*23, VM3*23, and VM23 (these mutations are centered in the lower stem domain), with wild-type PILIC in the same three T-cell lines and human
PBMCs.
much more stringent. In cells such as MT4 or PHA stimu- assays in the presence of purified, bacterially expressed
Tat protein (courtesy of Dr. John Brady, NCI). The Tat–lated PBMCs, perhaps upstream factors can interact with
Tat or general transcription factors to obviate the need TAR RNA gel shift assays were performed essentially
as described by Dingwall et al. (1989) (26). The bindingfor lower TAR stem. In this regard, it is interesting that
in both this and previous studies (15), viral replication reaction contained 20 pg of TAR RNA transcript, 1 mg
Tat, 25 mM Tris–HCl (pH 8.0), 50 mM NaCl, 1.5 mMin PHA-stimulated PBMCs was less dependent on TAR
structure. Thus, the TAR stem binding host cell factors MgCl2 , 0.5 mM DTT, 5 mM spermine, and 20 units of
RNasin (Promega, Madison, WI) in a 20-ml reaction. Aftermay represent a poorly understood class of transcrip-
tional regulators, whose role may vary in different cell incubation at 307 for 30 min, the reaction mixture was
analyzed by 6% native PAGE. TAR nuclear protein geltypes.
Several issues are raised by these results. Could the shift assays were essentially according to Rounseville
and Kumar (14). Briefly, the reaction mixture containedstructural alterations introduced into the TAR RNA stem
structure of VM5*23 and VM3*23 mutants also interfere 50% (vol/vol) nuclear extract (10 mg) in Dignam buffer D
(21), 1.5 mM MgCl2 and 10
5 cpm of radiolabeled TARwith Tat binding? We constructed the TAR domain mu-
tants into T7 expression plasmids and used in vitro-tran- RNA transcript (/1–/57 nt) in a total volume of 10 ml.
After incubation at room temperature for 15 min, a mix-scribed radiolabeled TAR RNA for gel mobility shift
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FIG. 2 —Continued
ture of RNase A and T1 was added and the reaction was VM23 gel shift shows some p140 binding (data not
shown). This partial binding (which may be greater incontinued for 15 min. The RNP complexes were analyzed
by native polyacrylamide gel electrophoresis as de- vivo) may be sufficient to restore viral replication to wild-
type levels in some cell types. Furthermore, in other stud-scribed previously (14). The results show that the Tat
binding domain within the introduced TAR mutants is ies with the TAR mutants which do not reconstitute TAR
RNA–protein complex in gel shift assays, we noticed theunaltered (Fig. 3A). It is likely that the Tat binding domain
of TAR remains unaltered in the proviral mutants in vivo presence of TAR binding protein by Western analysis
(Traviss et al., Unpublished results). This result suggestsand that the delayed growth rate is due to the destabiliza-
tion of p140 binding domain. Similarly the TAR RNA gel a role of auxillary factors in completion of the TAR RNA–
protein complex assembly.mobility shift assays, using VM5*23 and VM3*23 TAR
mutant transcripts in the presence of HeLa cell nuclear Although the results suggest an important role of lower
extract, showed an inhibition of TAR RNA–protein com- TAR RNA stem binding protein such as p140 in modulat-
plex formation (as compared to the wild type; Fig. 3B). ing HIV replication, they leave open the possibilities that:
(1) other host proteins, besides p140 might cooperate inThe mutant VM23, which restores the base-paired
structure of the lower TAR stem while altering its primary Tat function, and (2) it is the cooperative interaction of
these TAR RNA binding proteins that might determinesequence (Fig. 1), exhibits reduced RNP complex forma-
tion in vitro (Fig. 3B). The restoration of viral growth in the optimal Tat-mediated transcriptional trans-activation
(11–13). It appears that p140 is a necessary componentVM23 to the wild type level in some cell types suggests
that the integrity of the base paired structure of TAR is of the group of host proteins required for such host–viral
interactions since the p140 levels increased along withsufficient to allow normal growth. A dark exposure of
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FIG. 3. (A) Autoradiograph of 6% polyacrylamide gel showing a discrete complex formation between Tat and TAR RNAs. Complex formed between
Tat and TAR RNAs prepared by in vitro transcription from wild-type pT7TAR (WT), Lane 2; pT73*23 (3*23), lane 4; or pT75*23 (5*23), lane 6, using T7
RNA polymerases, and incubated with 1 ml of purified Tat protein (0.4 mg/ml) in the presence of 50 mM NaCl, 1.5 mM MgCl2 , and 0.5 mMDTT.
Lanes 1, 3, and 5 contain respective RNA transcript 15 only, no Tat protein. (B) RNase protection mobility shift assay. HeLa nuclear proteins were
incubated with radiolabeled TAR RNA in presence of 1.5 mM MgCl2 and 50 mM KCl, treated with RNases and analyzed by native polyacrylamide
gel electrophoresis as described in the text. An RNase-resistant RNA nuclear protein complex was formed when wild-type (WT) 32P-labeled TAR
RNA was incubated with HeLa nuclear extract (NE), Lane 2, but only weak RNP complexed formed with mutant TAR RNAs, lane 4 (TM 3*23), lane
6 (TM 5*23), and lane 8 (TM 23). Lanes 1, 3, and 5 contain respective RNA transcripts only, no nuclear proteins.
the efficiency of TAR–RNP complex formation in mito- blocked viral growth and that the resumption of viral
growth rate coincided with the restoration of the essen-genically stimulated primary human T-lymphocytes (17).
However, since the increase in p140 levels paralleled tial 5*-base-paired structure of TAR, emphasizes the evo-
lutionary importance of the lower TAR stem structure inthe efficiency of TAR RNA –protein complex formation in
most, but not in all cases (17), it is likely that other factors HIV-1 growth. These results redirect our focus on the
base paired 5* end of TAR RNA in promoting efficientin addition to p140 are necessary to nucleate the RNP
complex formation. viral replication; a notion that is also supported by the
pattern of evolution of the TAR structure (16). These re-Although the TAR RNA structure between /19 and
/48 has been shown to be sufficient for Tat function in sults necessitate a closer look at the role of the host cell
factors that bind specifically with this viral sequence intransient transfection assays (22–25), the lower stem
structure of TAR and the host factors that interact with modulating viral growth kinetics. An important issue will
be to decipher what specific host cell factors interactthis stem region may play a crucial role in viral growth;
perhaps by stabilizing Tat–TAR interaction for optimal with the TAR stem domain in regulating viral growth?
Here we describe our initial attempts to point out essen-transcriptional activation of integrated proviral DNA. The
fact that the disruptions of the lower stem structure tial roles host cell factors may play in integrating host–
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